SLRX Salarius Pharmaceuticals Inc: Sof marja

Salarius (SLRX) - korporativ logo

Salarius Pharmaceuticals (SLRX) oqsil-oqsil o'zaro ta'sir inhibitorlarini ishlab chiqish uchun yetakchi onkologlarni jalb qilmoqda. Biznes kapitalizatsiyasi grantlar va maqsadli saraton terapiyasi dori vositalarining kelgusidagi sotuvlariga tayanadi. GURU.Markets terminalining ushbu grafigi integral sof marja ko'rsatkichi foyda samaradorligini namoyish etishini ko'rsatadi, bunda 0.00 qiymati metrika darajasini belgilaydi. Kompaniyaning o'sish trayektoriyasi eksklyuziv ravishda klinik sinovlar natijalariga bog'liq.

salariuspharma.com (SLRX) - Kompaniya sotuv marjasi 04.07.2022dan 08.01.2026gacha

Salarius Pharmaceuticals (SLRX) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- aksiya kursi va ekspertlarning narx prognozi:
Kompaniyaning jamlanma tahliliyoti:Salarius Pharmaceuticals
Salarius Pharma ishlab chiqargan mahsulot

Salarius Pharmaceuticals (SLRX) bolalar onkologiyasi uchun noyob epigenetik dori vositalarini ishlab chiqmoqda va hozirda klinik sinovlarning ilk bosqichlarida turibdi. Tijorat sotuvlarining yo'qligi sof foyda hisob-kitoblarini operatsion xarajatlarga bog'liq qiladi, bu esa yakuniy daromadlilikka bevosita ta'sir ko'rsatadi. Ushbu ko'rsatkich har bir dollar daromadning foyda marjasini o'lchab, haqiqiy samaradorlikni spekulyativ tebranishlardan ajratadi. Sof foyda marjasini tahlil qilish aktivlarning haddan tashqari qimmat baholanganini o'z vaqtida aniqlash imkonini beradi. Investor ushbu grafik yordamida biznesning barqarorligini baholashi mumkin.

Raqobatdosh kompaniyalar

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|Erasca Oncology - Sotuvning sof marjinal rentabelligi|Sof foyda normasi DCTH (Delcath Corp)|YMAB: Sotuvning sof marjinal rentabelligi|AURA - Kompaniya sotuv marjasi|CADL (Candel Therapeutics Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi ARAY (Accuray)|Sof foyda bo'yicha sotuv rentabelligi SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Sof marja|Sof marja Citius Oncology, Inc. CTOR|HURA - Sof foyda bo'yicha sotuv rentabelligi|protaratx.com - Sotuvning sof marjinal rentabelligi|FATE - Sotuvning sof marjinal rentabelligi|WHWK: Sotuvning sof marjinal rentabelligi|TScan Therapeutics (TCRX) - Sotuvning sof marjinal rentabelligi|Sof marja Champions Oncology|Sof marja XBIT|Sotuvning sof marjinal rentabelligi CVM|Sof foyda bo'yicha sotuv rentabelligi OS Therapies Inc. OSTX|Sof marja Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Sof marja|ANL - Sof marja|Sof marja verupharma.com|TPST: Sotuvning sof marjinal rentabelligi|XLO - Kompaniya sotuv marjasi|Sof marja Renovaro|Sotuvning sof marjinal rentabelligi muraloncology.com|Sotuvning sof marjinal rentabelligi KAPA|Kompaniya sotuv marjasi OnKure Therapeutics, Inc.|Sotuvning sof marjinal rentabelligi GDTC (w2.cytomed.sg)|CRIS - Sof foyda bo'yicha sotuv rentabelligi|Apollomics - Sotuvning sof marjinal rentabelligi|Tharimmune Corp (THAR) - Sof foyda bo'yicha sotuv rentabelligi|ADVB: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi SBFM (Sunshine Biopharma)|Sof marja Xenetic Bio (XBIO)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)